Table 4.

Median hu14.18K322A pharmacokinetic parameters for patients treated on this trial and the phase I trial at the same hu14.18K322A dose (40 mg/m2/dose)

StudyBSA (m2)CL (L/day)/m2V1 (L)/m2AUC (mg*h/L)AUC (ng*h/L)/(mg/m2)Cmax (ng/mL)Cmax (ng/mL)/(mg/m2)Cend (ng/mL)Cend (ng/mL)/(mg/m2)T1/2 Alpha (days)T1/2 Beta (days)
Combined median (n = 13)0.780.6451.7996137.234,6301108392151.69.2
Range0.49–1.520.51–2.591.18–7.955,556–1,7499.3–47.413,543–50,908283–2,213148–1,0902.5–27.51.06–2.27.82–9.9
Navid et al. median (n = 3)0.981.263.8576219.126,3556591804.501.8513.71
Range0.76–2.021.06–1.663.81–3.92580—90514.5–22.620,955–27,125523–678162–3824.05–9.551.47–2.3113.50–14.61
  • Abbreviations: AUC, area under the plasma concentration–time curve; BSA, body surface area; CL, clearance; Cend, plasma concentration at the end of the infusion; Cmax, maximum plasma concentration; T1/2, half-life; Vl, volume.